InCarda Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- InCarda Therapeutics's estimated annual revenue is currently $1.6M per year.
- InCarda Therapeutics's estimated revenue per employee is $77,500
- InCarda Therapeutics's total funding is $77.9M.
Employee Data
- InCarda Therapeutics has 21 Employees.
- InCarda Therapeutics grew their employee count by -62% last year.
InCarda Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Operations | Reveal Email/Phone |
2 | Controller | Reveal Email/Phone |
3 | Senior Director | Reveal Email/Phone |
4 | Chief Operating and Technology Officer | Reveal Email/Phone |
5 | Director, Research | Reveal Email/Phone |
6 | Chief Financial Officer | Reveal Email/Phone |
7 | Contract Clinical Trial Manager | Reveal Email/Phone |
8 | N/A | Reveal Email/Phone |
9 | Clinical Research Associate | Reveal Email/Phone |
InCarda Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 21 | -62% | $77.9M | N/A |
What Is InCarda Therapeutics?
InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF).
keywords:N/A
$77.9M
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
-62%
Employee Growth %
N/A
Valuation
N/A
Accelerator
InCarda Therapeutics News
... Universiteitssingel 50, 6229 ER Maastricht, The Netherlands; or Luiz Belardinelli, MD, InCarda Therapeutics Inc, 39899 Balentine Dr,...
Flecainide has been around to treat atrial fibrillation since the '80s, but Grace Colón, CEO of InCarda Therapeutics, thinks it needs a face-lift. Armed with $30 million in venture funding, InCarda hopes to make the drug available as an at-home inhalable treatment for patients in the early stage ...
InCarda Therapeutics — which is developing an inhaled paroxysmal atrial fibrillation drug — filed an SEC Form D confirming the sale of more than $35 million in equity. The Newark, Calif.–based drug-device combo company sold nearly $35.3 million since the first sale of the offering occurred on O ...
InCarda Therapeutics, Inc., a San Francisco, CA-based biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, raised over $5m Series A financing. Potential additional tranches can bring to a total of $1.5m ...
Other Companies in Newark
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 21 | 11% | N/A |
#2 | $2.1M | 21 | N/A | N/A |
#3 | $2.1M | 21 | N/A | N/A |
#4 | $1.8M | 21 | 5% | N/A |
#5 | $3.6M | 21 | -65% | N/A |